Australia
FlexRule®, the strongest contender, offers a mighty Decision Platform, says Forrester
MELBOURNE, Australia, June 7, 2023 /PRNewswire/ -- Forrester recognized FlexRule®, a rapidly growing end-to-end decision management and automation provider, as "a good fit for customers that want a solid, comprehensive decisioning platform" in theForrester Wave™: AI Decisioning Platforms, Q2 2023...
Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK
Mitra® and hemaPEN® receive regulatory certification as medical devices for remote blood sample collection in healthcare, clinical trials and home monitoring programs inEurope and United Kingdom. MELBOURNE, Australia, June 2, 2023 /PRNewswire/ -- Trajan Scientific and Medical, a leading provider...
Aravax doses first patient in Phase 2 peanut allergy clinical trials
MELBOURNE, Australia, June 1, 2023 /PRNewswire/ -- The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U....
Sky's the limit with Fiji Airways' global sale
Fiji Airways launches up to 38% off return airfares from Canada to Fiji, Australia, New Zealand and Pacific Islands. NADI, Fiji, June 1, 2023 /PRNewswire/ -- Guests can score up to 38% off Fiji Airways flights to popular destinations includingFiji, Pacific Islands, New Zealand and Australia wit...
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...
QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...
FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health
Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey MELBOURNE, Australia and INDIANAPOLIS, May 2...
TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I
SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial inAustralia. The trial will be a randomized, double-b...
Clarity's theranostic prostate cancer trial advances to cohort 2
Highlights * Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. * No dose limiting toxicities (DLTs) have been reported in cohort 1. * The Sa...
Blue Star on track for first helium production and sales from Voyager in Q4 CY2023
PERTH, Australia, May 22, 2023 /PRNewswire/ -- Blue Star Helium Limited (ASX:BNL, OTCQB:BSNLF) ("Blue Star" or the "Company") provides an update on progress at its maiden Voyager helium development inLas Animas County, Colorado. Highlights: * Three well drilling program at high-grade Voyager d...
TargetRecruit Expands its Global Presence with New Office in Sydney
SYDNEY, May 18, 2023 /PRNewswire/ -- TargetRecruit, a leading provider of enterprise software for recruitment firms, built on Salesforce, is thrilled to announce the opening of its new office here inSydney. Situated in the heart of Sydney's Central Business District (CBD), the new office will ...
Matt Hill Projects Expands, Reimagines Art/Sculptures for Commercial & Residential Spaces
MELBOURNE, Australia and LOS ANGELES, May 16, 2023 /PRNewswire/ -- Matt Hill Projects is recognized as a leading designer and fabricator of steel sculptures ranging from custom animals to illuminated cubes and spheres along with architectural facades, and the company is expanding rapidly due to h...
Symbio's South-East Asia Hub unlocks multi-country access with one interconnect
SYDNEY, May 16, 2023 /PRNewswire/ -- Symbio Holdings Limited (ASX: SYM), a leading voice communications software provider, today announced the launch of itsSouth-East Asia (SEA) Regional Hub. Launching across Singapore and Malaysia initially, Symbio's SEA Regional Hub will provide cost efficient,...
Symbio to unlock Malaysia domestic communications market with network launch
SYDNEY, May 12, 2023 /PRNewswire/ -- Industry-leading communications software and cloud infrastructure provider Symbio Holdings (ASX:SYM) officially launched its domestic network inMalaysia today, with live call traffic and several large global customers already trialling it. Symbio's entry in...
Replica Studios' new Style Morphing feature gives game developers access to over 1,000 emotions for AI-synthesized voices
Developers now have greater control over the emotional range of Replica's AI voices SYDNEY, May 9, 2023 /PRNewswire/ -- Replica Studios, developer of a leading artificial intelligence (AI) voice platform for video games, has announced its new Style Morphing feature that allows game developers to...
6clicks Evolves Hub & Spoke Management and Single Pane of Glass Visibility for Latest GRC Challenges
New 6clicks platform enables completely customizable balance between
centralization and decentralization for global businesses, advisors and MSPs
MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- 6clicks
FlexRule® recognized as a Top Decision Management and Automation Platform by Forrester
MELBOURNE, Australia, April 26, 2023 /PRNewswire/ -- FlexRule® was positioned as
a top decision management and automation platform by Forrester's AI
Decisioning Platforms Landscape, Q1 2023.
The report says enterprises can leverage FlexRule®
Mediso launches next generation MRI spectrometer spinScan®
BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso
Week's Top Stories
Most Reposted
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 293 media titles]
2026-09-22 18:37Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45